aTYR PHARMA (ATYR) Accounts Payables (2014 - 2026)
aTYR PHARMA's (ATYR) quarterly Accounts Payables came in at $2.8 million in Q1 2026, up 79.95% YoY from $1.5 million in Q1 2025, and down 29.2% on a QoQ basis from $3.9 million in Q4 2025.
aTYR PHARMA (ATYR) Accounts Payables (2014 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has 13 years of Accounts Payables data on file, last reported at $2.8 million in Q1 2026.
- Quarterly Accounts Payables rose 79.95% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (up 79.95% YoY) and the FY2025 annual result came in at $3.9 million, down 9.99% from the prior year.
- Accounts Payables slipped to $2.8 million in Q1 2026, from $3.9 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $4.9 million in Q1 2024 to a low of $516000.0 in Q2 2023.
- A 5-year average of $2.9 million and a median of $3.1 million in 2022 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2022 — Accounts Payables surged 247.67% — and 2023, when it tumbled 69.18%.
- Tracing ATYR's Accounts Payables over 5 years: stood at $3.1 million in 2022, then advanced by 13.62% to $3.5 million in 2023, then rose by 22.5% to $4.3 million in 2024, then declined by 9.99% to $3.9 million in 2025, then declined by 29.2% to $2.8 million in 2026.
- The last three Accounts Payables figures came in at $2.8 million (Q1 2026), $3.9 million (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | aTYR PHARMA | 49.54 Mn | -7.87 Mn | - | 3.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.24 Mn |
| Mar 31, 2026 | 2.76 Mn |
| Dec 31, 2025 | 3.89 Mn |
| Sep 30, 2025 | 4.06 Mn |
| Jun 30, 2025 | 3.88 Mn |
| Mar 31, 2025 | 1.53 Mn |
| Dec 31, 2024 | 4.32 Mn |
| Sep 30, 2024 | 3.95 Mn |
| Jun 30, 2024 | 1.26 Mn |
| Mar 31, 2024 | 4.89 Mn |
| Dec 31, 2023 | 3.53 Mn |
| Sep 30, 2023 | 2.04 Mn |
| Jun 30, 2023 | 516,000.00 |
| Mar 31, 2023 | 3.97 Mn |
| Dec 31, 2022 | 3.11 Mn |
| Sep 30, 2022 | 3.13 Mn |
| Jun 30, 2022 | 1.67 Mn |
| Mar 31, 2022 | 1.56 Mn |
| Dec 31, 2021 | 1.03 Mn |
| Sep 30, 2021 | 900,000.00 |